Hansen Gwenn, Chief Scientific Officer of Nurix Therapeutics ($NRIX), made five open market sales of company shares over the last year, totaling $224,134. The most recent sale occurred on January 30, 2026. These transactions rank 8,178th out of 11,678 insiders by sale value, well below the average of $8.6 million across 6.37 transactions per seller. Gwenn recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 10, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Restricted Stock Units | 42875 | $0.00 | 42,875.0000 | 102,843,012 | 9999.99% | 0.04% |
| Feb. 10, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 93750 | $0.00 | 93,750.0000 | 102,843,012 | 9999.99% | 0.09% |
| Feb. 3, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Employee Stock Option (right to buy) | 31333 | $0.00 | 0.0000 | 102,843,012 | 100.00% | 0.03% |
| Feb. 3, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 31333 | $0.84 | 115,005.0000 | 102,843,012 | 37.45% | 0.03% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 85,708.0000 | 102,843,012 | 4.58% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2859 | $0.00 | 88,567.0000 | 102,843,012 | 3.34% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 4797 | $16.58 | 83,770.0000 | 102,843,012 | 5.42% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 98 | $17.37 | 83,672.0000 | 102,843,012 | 0.12% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 0.0000 | 102,843,012 | 100.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 18,750.0000 | 102,843,012 | 16.67% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 2,000.0000 | 102,843,012 | 50.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2859 | $0.00 | 25,725.0000 | 102,843,012 | 10.00% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 79,958.0000 | 102,843,012 | 4.18% | 0.00% |
| Jan. 30, 2026 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 81,958.0000 | 102,843,012 | 2.50% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 4,000.0000 | 76,883,436 | 33.33% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 4087 | $12.80 | 76,751.0000 | 76,883,436 | 5.06% | 0.01% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2858 | $0.00 | 80,838.0000 | 76,883,436 | 3.67% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 77,980.0000 | 76,883,436 | 5.05% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 74,230.0000 | 76,883,436 | 2.77% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 72,230.0000 | 76,883,436 | 4.65% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2858 | $0.00 | 28,584.0000 | 76,883,436 | 9.09% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 22,500.0000 | 76,883,436 | 14.29% | 0.00% |
| Oct. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 3,207.0000 | 76,883,436 | 50.00% | 0.00% |
| Oct. 14, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Restricted Stock Units | 20000 | $0.00 | 20,000.0000 | 76,883,436 | 9999.99% | 0.03% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 64,723.0000 | 75,886,817 | 5.21% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 70,473.0000 | 75,886,817 | 5.62% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 66,723.0000 | 75,886,817 | 3.09% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2858 | $0.00 | 31,442.0000 | 75,886,817 | 8.33% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 26,250.0000 | 75,886,817 | 12.50% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 6,000.0000 | 75,886,817 | 25.00% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 6,414.0000 | 75,886,817 | 33.33% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2858 | $0.00 | 73,331.0000 | 75,886,817 | 4.06% | 0.00% |
| July 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 4308 | $12.01 | 69,023.0000 | 75,886,817 | 5.87% | 0.01% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 64,893.0000 | 75,886,817 | 6.13% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3206 | $0.00 | 59,143.0000 | 75,886,817 | 5.73% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 61,143.0000 | 75,886,817 | 3.38% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 3377 | $11.50 | 61,516.0000 | 75,886,817 | 5.20% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3206 | $0.00 | 9,621.0000 | 75,886,817 | 24.99% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 8,000.0000 | 75,886,817 | 20.00% | 0.00% |
| April 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 30,000.0000 | 75,886,817 | 11.11% | 0.00% |
| Feb. 11, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 75,886,817 | 9999.99% | 0.10% |
| Feb. 11, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Restricted Stock Units | 34300 | $0.00 | 34,300.0000 | 75,886,817 | 9999.99% | 0.05% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 33,750.0000 | 75,886,817 | 10.00% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 53,877.0000 | 75,886,817 | 6.33% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 55,877.0000 | 75,886,817 | 3.71% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 59,627.0000 | 75,886,817 | 6.71% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 3357 | $19.81 | 56,270.0000 | 75,886,817 | 5.63% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 333 | $20.33 | 55,937.0000 | 75,886,817 | 0.59% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 12,827.0000 | 75,886,817 | 20.00% | 0.00% |
| Jan. 30, 2025 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 10,000.0000 | 75,886,817 | 16.67% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 37,500.0000 | 72,779,381 | 9.09% | 0.01% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 16,034.0000 | 72,779,381 | 16.67% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 54,107.0000 | 72,779,381 | 7.45% | 0.01% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 3437 | $24.31 | 50,670.0000 | 72,779,381 | 6.35% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 50,357.0000 | 72,779,381 | 4.14% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 48,357.0000 | 72,779,381 | 7.10% | 0.00% |
| Oct. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 12,000.0000 | 72,779,381 | 14.29% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 44,808.0000 | 54,337,901 | 4.67% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 42,808.0000 | 54,337,901 | 8.10% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3750 | $0.00 | 41,250.0000 | 54,337,901 | 8.33% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 14,000.0000 | 54,337,901 | 12.50% | 0.00% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 19,241.0000 | 54,337,901 | 14.29% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 3408 | $20.67 | 45,150.0000 | 54,337,901 | 7.02% | 0.01% |
| July 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3750 | $0.00 | 48,558.0000 | 54,337,901 | 8.37% | 0.01% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3206 | $0.00 | 39,608.0000 | 54,337,901 | 8.81% | 0.01% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 41,608.0000 | 54,337,901 | 5.05% | 0.00% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 2007 | $12.04 | 39,601.0000 | 54,337,901 | 4.82% | 0.00% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3206 | $0.00 | 22,448.0000 | 54,337,901 | 12.50% | 0.01% |
| April 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 16,000.0000 | 54,337,901 | 11.11% | 0.00% |
| Feb. 13, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Restricted Stock Units | 45000 | $0.00 | 45,000.0000 | 54,337,901 | 9999.99% | 0.08% |
| Feb. 13, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 54,337,901 | 9999.99% | 0.28% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 2334 | $7.99 | 36,402.0000 | 54,337,901 | 6.03% | 0.00% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 25,654.0000 | 54,337,901 | 11.11% | 0.01% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 18,000.0000 | 54,337,901 | 10.00% | 0.00% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 36,736.0000 | 54,337,901 | 9.56% | 0.01% |
| Jan. 30, 2024 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 38,736.0000 | 54,337,901 | 5.44% | 0.00% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 20,000.0000 | 48,607,990 | 9.09% | 0.00% |
| Oct. 31, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 1633 | $5.20 | 33,529.0000 | 48,607,990 | 4.64% | 0.00% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 35,162.0000 | 48,607,990 | 6.03% | 0.00% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 33,162.0000 | 48,607,990 | 10.71% | 0.01% |
| Oct. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 28,861.0000 | 48,607,990 | 10.00% | 0.01% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 29,839.0000 | 48,607,990 | 12.04% | 0.01% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 32,068.0000 | 48,607,990 | 9.09% | 0.01% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 2000 | $0.00 | 22,000.0000 | 48,607,990 | 8.33% | 0.00% |
| July 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 2000 | $0.00 | 31,839.0000 | 48,607,990 | 6.70% | 0.00% |
| July 31, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 1884 | $9.65 | 29,955.0000 | 48,607,990 | 5.92% | 0.00% |
| April 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3206 | $0.00 | 27,768.0000 | 48,607,990 | 13.05% | 0.01% |
| April 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3206 | $0.00 | 35,275.0000 | 48,607,990 | 8.33% | 0.01% |
| May 1, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 1136 | $9.88 | 26,632.0000 | 48,607,990 | 4.09% | 0.00% |
| Feb. 14, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 88900 | $0.00 | 88,900.0000 | 48,607,990 | 9999.99% | 0.18% |
| Feb. 14, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | A | Restricted Stock Units | 24000 | $0.00 | 24,000.0000 | 48,607,990 | 9999.99% | 0.05% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Restricted Stock Units | 3207 | $0.00 | 38,481.0000 | 48,607,990 | 7.69% | 0.01% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | M | Common Stock | 3207 | $0.00 | 24,421.0000 | 48,607,990 | 15.12% | 0.01% |
| Jan. 30, 2023 | Nurix Therapeutics, Inc. | $NRIX | Hansen Gwenn | Chief Scientific Officer | S | Common Stock | 1412 | $11.78 | 23,009.0000 | 48,607,990 | 5.78% | 0.00% |